Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 258

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 258
---
-retirement benefits                      20                   -                   -   
Stock-based compensation                     411           121                        44   
Compensation                               2,018               1,465               1,015   
of key management                                                                          
 
Most of the employment agreements entered into between the Company and its executive officers include termination provisions, whereby the executive officers would be entitled to receive benefits that would be payable if the Company were to terminate the executive officers’ employment without cause or if their employment is terminated following a change of control. Separation benefits generally are calculated based on an agreed-upon multiple of applicable base salary and incentive compensation and, in certain cases, other benefit amounts.
 
During the year ended December 31, 2024, the Company made payments for research and development expenditures to Angiogenesis Foundation for which a Director of the Company is the CEO of the Foundation of $50 (2023 - $201 and 2022 - $105). These transactions are in the normal course of operations and are measured at the amount of consideration established and agreed to by the related parties.
 

28.   Subsequent
        event   
----------------
Tariffs
 
On February 1, 2025, the President of the United States issued three executive orders directing the United States to impose new tariffs on imports originating from Canada, Mexico, and China. These orders call for additional 25% duty on imports into the United States of Canadian-origin and Mexican-origin products and 10% duty on Chinese-origin products, except for Canadian energy resources that are subject to an additional 10% duty.
 
On April 2, 2025, the orders in regard to goods imported from Canada and Mexico that are compliant with the Canada-United States-Mexico Agreement were suspended for a one-month period. The Company is assessing the direct and indirect impacts to its business of such tariffs, retaliatory tariffs or other trade protectionist measures as this situation develops.
 

F-45
----